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Summary
Ataxia with vitamin E deficiency (AVED), or familial
isolated vitamin E deficiency, is a rare autosomal reces-
sive neurodegenerative disease characterized clinically by
symptoms with often striking resemblance to those of
Friedreich ataxia. We recently have demonstrated that
AVED is caused by mutations in the gene for a-tocoph-
erol transfer protein (a-TTP). We now have identified a
total of 13 mutations in 27 families. Four mutations
were found in x2 independent families: 744delA, which
is the major mutation in North Africa, and 513insTT,
486delT, and R134X, in families of European origin.
Compilation of the clinical records of 43 patients with
documented mutation in the a-TTP gene revealed dif-
ferences from Friedreich ataxia: cardiomyopathy was
found in only 19% of cases, whereas head titubation
was found in 28% of cases and dystonia in an additional
13%. This study represents the largest group of patients
and mutations reported for this often misdiagnosed dis-
ease and points to the need for an early differential di-
agnosis with Friedreich ataxia, in order to initiate ther-
apeutic and prophylactic vitamin E supplementation
before irreversible damage develops.
Introduction
Two forms of autosomal recessive ataxia caused by vi-
tamin E deficiency have been described. The first form
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to be identified was abetalipoproteinemia (OMIM
200100 [http://www3.ncbi.nlm.nih.gov:80/htbin-post/
Omim/dispmim?200100]), in which gastrointestinal ab-
sorption of lipids is impaired owing to the failure of
formation of chylomicrons and the absence of very-low-
density lipoproteins (VLDLs) and low-density lipopro-
teins (Kayden and Traber 1991). This results in severely
reduced levels of serum vitamin E. This condition is due
to mutations in the gene coding for the microsomal tri-
glyceride transfer protein (Sharp et al. 1993). In the sec-
ond form, familial isolated vitamin E deficiency
(FIVE; OMIM 277460 [http://www3.ncbi.nlm.nih.gov:
80/htbin-post/Omim/dispmim?277460]), gastrointesti-
nal absorption of lipids is normal but incorporation of
vitamin E into VLDLs secreted by the liver is impaired
(Traber et al. 1990, 1993). In normal individuals, the
latter function accounts for the efficient recycling of
plasma vitamin E ( pools/d) that otherwise is1.4 0.6
rapidly eliminated (Traber et al. 1994). FIVE has been
described in rare cases, studied during the period
1981–89 (Burck et al. 1981; Laplante et al. 1984; Har-
ding et al. 1985; Krendel et al. 1987; Stumpf et al. 1987;
Yokota et al. 1987; Kohlschu¨tter et al. 1988; Sokol et
al. 1988; Trabert et al. 1989). The description, reported
in 1993, of eight affected individuals from two large
Tunisian pedigrees (Ben Hamida et al. 1993b) initiated
the identification of many other patients from North
Africa, where this condition appears to be much more
frequent. In the original study of Tunisian families,
the clinical presentation was very similar to the se-
vere Friedreich ataxia (OMIM 223300 [http://
www3.ncbi.nlm.nih.gov:80/htbin-post/Omim/dispmim?
223300]) phenotype, and the condition was named
“ataxia with vitamin E deficiency” (AVED; OMIM
277460 [http://www3.ncbi.nlm.nih.gov:80/htbin-
post/Omim/dispmim?277460]). We localized the defec-
tive gene in proximal 8q by linkage analysis, homozy-
gosity mapping, and linkage-disequilibrium analysis
(Ben Hamida et al. 1993a; Doerflinger et al. 1995). The
gene coding for the a-tocopherol transfer protein (a-
TTP) was localized independently to 8q13 (Arita et al.
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1995). The identification of mutations in the a-TTP gene
confirmed that deficiency of vitamin E is the sole cause
of the neurological symptoms in AVED. All North Af-
rican and southern Italian patients studied were ho-
mozygous for the same frameshift mutation, 744delA
(Ouahchi et al. 1995). Five other mutations were found
in isolated families of north European and of Japanese
origin (530AGr6 and 513insTT [Ouahchi et al. 1995],
486delT and R192H [Hentati et al. 1996], and H101Q
[Gotoda et al. 1995]). We report here the identification
of seven additional mutations in families of very diverse
origins. A comparison of all the mutations reported to
date, with the clinical presentation and progression of
the disease before initiation of a-tocopherol supplemen-
tation, documents a correlation between the severity of
the disease and the type of mutation.
Subjects and Methods
Subjects
Twenty-seven AVED families, comprising 41 patients,
were included in the study. Essential criteria were very
low vitamin E (!2.5 mg/liter) and neurological symp-
toms in the absence of fat malabsorption or abetalipo-
proteinemia. The numbering of families 1–16 is accord-
ing to the study by Ouahchi et al. (1995). Families 3
and 4 (referred by M. Ben Hamida) and 9 and 17 (re-
ferred by A. Benomar) belong to large series of Tunisian
and Moroccan families, respectively, and are not part of
this study. Clinical descriptions were reported elsewhere
for families 13 (Burck et al. 1981; Kohlschu¨tter et al.
1988), 18 (Laplante et al. 1984), 14 (Sokol et al. 1988),
16 (Trabert et al. 1989), 1 and 2 (Ben Hamida et al.
1993b), 8 (Amiel et al. 1995), and 28 (Martinello et al.,
in press), and mutation was reported for 10 families
(Ouahchi et al. 1995). In addition to the 27 families
analyzed here, molecular and clinical data from 6 fam-
ilies were compiled from the literature (Gotoda et al.
1995; Hentati et al. 1996; Yokota et al. 1996, 1997).
Cloning of a-TTP Genomic Fragments
Approximately 106 clones from a l GEM12 human
genomic library (provided by Dr. J. M. Garnier) were
screened with the 765-bp EcoRI cDNA fragment, cor-
responding to exons 1–4 and part of exon 5 (Arita et
al. 1995), which was labeled by the random-priming
method. One positive clone for exon 1 and one positive
clone for exon 2 were isolated and were digested by
EcoRI. The EcoRI fragments that contained an exon
were subcloned by pBluescript (Stratagene) and were
sequenced with cDNA-derived primers (Arita et al.
1995), followed by sequencing with intronic primers on
the other strand.
SSCP Analysis
Primers used for amplification of exons 3–5 have been
reported (exons a–c in Ouahchi et al. 1995). Primers
designed for amplification of the 5′ UTR and of exons
1 and 2 are as follows, with the annealing temperature
and MgCl2 and dimethyl sulfoxide (DMSO) concentra-
tions for PCR given in parentheses: 5′ UTR1, D-GAG
GCT GCC AAG GAG GCA and R-GAA GCC ACT
GATGTTCAAACAC, and 5′ UTR2, D-AATCATCCC
AAC TAA CTT TGA CAT and R-GCC TCT GCC ATG
CCC GC (59C, 1.5 mM MgCl2, 5% DMSO); exon 1a,
D-TGC GGC CGC AGC AGC and R-CGG GCG CGC
AGG AACC (60C, 1 mM MgCl2, 5% DMSO); exon
1b, D-AAG CTG GCG TCC CGCT and R-TGA GGT
GCG CAC TGC CG (58C, 1.5 mM MgCl2, 5%
DMSO); and exon 2, D-TTA CCA TGT ATG CCA TTT
GTA and R-AGG GAA CAC AAC TGA ACT GGA
(52C, 1.5 mM MgCl2, no DMSO). The “D” and “R”
labels indicate primers in the coding and the noncoding
direction, respectively. Exons were amplified in the pres-
ence of a[-32P]dCTP, as described elsewhere (Duclos et
al. 1994). Two microliters of PCR products was diluted
in 10 ml of 10 mM EDTA and 0.1% SDS, and 2 ml of
the dilution was mixed in 8 ml 95% formamide, 20 mM
EDTA, 0.05% xylene cyanol, and 0.05% bromophenol
blue. DNA was denatured for 5 min at 80C and was
kept on ice for x2 min. Four microliters of the mix was
loaded onto 10% glycerol–6% polyacrylamide gels. The
nondenaturing gels were run at 20 W for 8 h at room
temperature or at 5 W overnight at 4C. Gels were trans-
ferred to Whatman 3MM paper, were dried under vac-
uum, and were exposed overnight to X-AR Kodak film,
with an intensifying screen.
Sequencing of Variant Bands
Variant bands were excised from dried SSCP gel,
soaked overnight in 100 ml bidistilled water, 5 ml of
which was reamplified by PCR. PCR fragments then
were purified with the Geneclean kit (Bio101) and were
precipitated by ethanol. Fragments were sequenced with
a Taq cycle sequencing kit (Applied Biosystems), by use
of fluorescent dideoxynucleotides and one of the PCR
primers. Reaction products were run on an automated
DNA sequencer (model 373A; Applied Biosystems). All
sequences on both strands were determined.
Microsatellite Genotyping
Microsatellite genotyping with markers linked to the
AVED locus has been described elsewhere (Doerflinger
et al. 1995). Haplotypes were constructed on the basis
of alleles from at least one parent or from two children
and the patient’s wife, and no recombination was de-
tected (data not shown).
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Table 1
5′ UTR and Flanking Intron Sequences of the First Two Exons of the a-TTP Gene
Exon Sequence
Promoter and 5′ UTR GAGGCTGCCAAGGAGGCATTATGGAATGCGTGTTTTAGAATGCATGCTGTAATC
CAGTGCGAGGCGAGGGGTCATCAGTCTGGAATCTGATGGAAGGAGAAGGGA
GAGGGCTCAGTAGCGCGTCGGCCACTGGCCATTAAAGGCTCGTTCTAAGGC
TCCTTTCAGCTCCAAGATTGCAAGAAGGAAGGAAGAATGGAAGGAAGAGAG
AGGGAGGAAGGAAAAAGAAAAAAAAAAAGATTCTTTAGTAGATCGTAAAAA
TCATCCCAACTAACTTTGACATCGTTTCCTCGGTGTTTGAACATCAGTGGC
TTCCCTCGCTGGGAAAAAGCTGGGGTCCCTAACTAAAGCTGCTAAACAGGT
GGCTAGCACCCGTGGGGACACTGTGCGGTTTCCTTTAAGAGGCAGCTCTGC
TCGCCGCGGGTCCGGCGTGCGAGGCCGGAGACCGCCCTGCCAGGCTGGAGA
GTGGTTGTGCGACGGGCAGCGGCCGCAGAGGCGGGGCCGAGGGTGGCGCGG
GGCGCGCGCTTTTCCCGGGTGCCCGGGTAGCTGCGGCCGCAGCAGCGG
CGGCGGGCAtg 3
1 Donor 203 ggGTAAGCGTGCGTGCCCAGGGCGCTCGGCAGTGCGCACCTCACCCGC
CCCGTCCCCCGCCCCACGACCCCGGATATCTG
2 Acceptor TTA CCATGTATGCCATTTGTAGACAATTTTAATTTTATTTTTCAGtt 206
2 Donor 357 cgGTAAGTCATACACAACTCTTTTTTTTTTCTCCTCTCCTCCAGTTCA
GTTGTGTTCCCT CCCCTCTCCTCTTCTCTCTTTCTTCCATTTCTTCCTTGA
ATACCATATAGAAAGCTTCAATGCATTCATCTTTAGGAA
NOTE.—The first two or last two nucleotides of the exons are given in lowercase letters, and their position is
indicated by a number preceding or following the cDNA sequence (Arita et al. 1995). Sequences used for design of
the PCR primers are underlined. The 5′ UTR, exon 1, and flanking intron 1 sequences have been submitted to Genbank
(accession AF031323; http://www.ncbi.nlm.nih.gov/Web/Genbank/), as well as have the exon 2 and flanking intron
sequences (accession AF031324).
Table 2
Novel Mutations in the a-TTP Gene of AVED Patients
Exon
Nucleotide
Change
Effect on Coding
Sequence
Corresponding
Amino Acid in
Rat a-TTP, h-
CRALBP, and
SEC14pa
1 175CrT R59W R, R, R
2 205-1GrC Skipping of exon
2 and frameshift
after R68
)
2 306ArG No change on
G102 (possible
splice-site
activation)
)
2 358GrA A120T S, E, N
3 400CrT R134X, protein
truncation
)
3 421GrA E141K E, E, Q
4 661CrT R221W R, R, K
a For the missense mutations only (h-CRALBP denotes human
CRALBP; and SEC14p denotes yeast SEC14 protein).
Statistical Analysis
Means were compared by use of the Kruskal/Wallis
test (modified Student’s t-test), and frequencies were
compared by use of the x2 test. Means are given with
SDs.
Results
In order to search for mutations in the 5′ portion of
the coding sequence, we completed the determination of
the genomic organization of the a-TTP gene. Two in-
dependent l genomic clones were isolated with a 5′
cDNA probe (Arita et al. 1995), and each clone con-
tained a different exon that was distinct from the three
terminal exons reported elsewhere (Ouahchi et al. 1995).
Sequencing of the exons indicated that the transcript is
encoded entirely by the five exons. The 5′ UTR and the
intron sequences flanking exons 1 and 2 are given in
table 1. The exon-intron structure had been established
independently by Hentati et al. (1996). Primers were
designed to amplify the 5′ UTR and exons 1 and 2, from
genomic DNA of the patients. Because of its length and
high GC content, exon 1 was amplified in two over-
lapping fragments.
Mutations were searched, by SSCP, in the 5′ UTR
and in all five exons, followed by direct sequencing of
the variant band. The mutations described else-
where—744delA, 513insTT (initially described errone-
ously as 513insTC) (Ouahchi et al. 1995), and 486 delT
(Hentati et al. 1996)—were found in one or more ad-
ditional families. Seven novel mutations were found (ta-
ble 2 and fig. 1). Two mutations, one nonsense (R134X)
and one acceptor–splice-site mutation (205-1GrC), pre-
dict a major disruption of a-TTP synthesis. One family
(21) with a 513insTT mutation on one chromosome
presented a 306ArG change on the other chromosome.
This mutation leaves invariant the glycine residue at po-
sition 102. However, it was never found in 80 unrelated
normal chromosomes, and no other variation was de-
tected in the coding sequence bearing the 306ArG var-
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Figure 1 Distribution of a-TTP mutations. Unblackened boxes
indicate coding sequences, and blackened boxes indicate 5′ and 3′ (par-
tial) UTRs. Hatched areas indicate highly conserved domains in
CRALBP and SEC14 (Arita et al. 1995). The nucleotide positions of
the exon boundaries are indicated above the bar, and the positions of
mutations are indicated below the bar. Novel mutations described in
this study are underlined. The deletions and insertions are represented
by upward-pointing and downward-pointing triangles, respectively;
splice mutations are represented by a left-pointing (acceptor site) or
a right-pointing (potential donor site) arrow; and nonsense and mis-
sense mutations are represented by upward-pointing arrows.
iation, suggesting that it might be disease causing, pos-
sibly by activation of a cryptic splice site (A/GTCCTrG/
GTCCT). The remaining four mutations were missense
mutations (table 2). Comparison of the mutated amino
acids to the corresponding amino acids in the related cis
retinaldehyde binding protein (CRALBP) and yeast
SEC14 protein (Arita et al. 1995) revealed that three
missense mutations were nonconservative substitutions
(R59W, E141K, and R221W) that altered highly con-
served amino acids (identical in CRALBP and identical
or with a conservative change in SEC14) (table 2). In
contrast, the A120T mutation is a semiconservative sub-
stitution of an amino acid that is not conserved in
CRALBP, SEC14, or even rat a-TTP (Arita et al. 1995).
We also confirmed the presence of the missensemutation
R192H on the maternal chromosome of family 14 (Hen-
tati et al. 1996). These four missense mutations and the
nonsense mutation were changes of a CpG dinucleotide
into TpG or CpA. Both the R192H mutation and the
previously described H101Q missense mutation (Go-
toda et al. 1995) are semiconservative substitutions of
amino acids that are not conserved in CRALBP and
SEC14.
Mutation in the a-TTP coding sequence was not
found in four independent patients with isolated low
vitamin E deficiency and Friedreich ataxia–like symp-
toms, even after direct sequencing of all exons and of
the 5′ UTR. Analysis with closely linked markers (Doer-
flinger et al. 1995) showed that one of these patients
(family 15), from a first-degree consanguineous mar-
riage, was homozygous for eight contiguous markers
encompassing the a-TTP locus (not shown), therefore
suggesting linkage to the AVED locus (odds of 16:1 in
favor of linkage). The three other patients were neither
from consanguineous parents nor homozygous for the
linked markers. It seems unlikely that they carry two
distinct mutations not detected by SSCP of the coding
and flanking intronic sequences, and, therefore, they
may suffer from another vitamin E deficiency that may
or may not be inherited. Haplotype analysis also was
used to test whether identical mutations found in in-
dependent families have distinct or common origins. The
haplotype linked with the 513insTTmutation in families
14 and 21 was identical over four contiguous markers,
which is evidence in favor of a common ancestor. The
haplotypes linked with the R134X mutation in two Ca-
nadian families (20 and 31) were different, suggesting
recurrent, independent mutations, which is not unex-
pected for a change in a CpG dinucleotide.
In order to correlate the mutations with disease se-
verity, the clinical features of the patients were compiled
(table 3; features of the four patients with no identified
mutation also are given, for comparison). The large
amount of data collected from patients with documented
mutations (total of 43 patients in 29 families), including
the 6 patients reported by other groups, provided the
opportunity to assess the diagnostic criteria for AVED
and to explore phenotypic variability. Age at onset was
within the range of 2–52 years, but onset at age 120
years was reported in only seven cases. In general, most
patients fulfilled diagnostic criteria corresponding to
Friedreich ataxia (Harding 1981; Du¨rr et al. 1996), in-
cluding cerebellar ataxia, dysarthria, reduced or absent
deep tendon reflexes, and vibratory-sense disturbances
(table 4). However, cardiomyopathy, an important cri-
terion for Friedreich ataxia, was found in only eight
patients, with two cases documented by echocardio-
graphy and six cases by electrocardiography alone
( ; , for the difference between AVED2x  21 P ! .0005
and Friedeich ataxia). On the other hand, head tituba-
tion was found in 11 (28%) of 39 cases for which in-
formation was available, but it usually is not found in
Friedreich ataxia patients ( ; ). Four pa-2x  37 P ! .0005
tients (13%) who did not have head titubation had dys-
tonia. Four patients had marked retinopathy, and two
had moderately reduced amplitude on an electroretin-
ogram. Amplitude of median sensory-nerve conduction
was normal in six patients, was reduced in five patients,
and was undetectable in three patients (data not shown).
No case, of the 16 for which information was available,
had diabetes (data not shown). Age when wheelchair
bound or age at last examination when still ambulatory
also is given in table 3, even though persistence of am-
bulation is dependent largely on when vitamin
E–supplementation therapy was initiated. In one case
(family 18), ambulation was lost just prior to initiation
of treatment and was recovered thereafter.
Clinical findings were compared between two groups
of families—families in which the patients had two trun-
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cating mutations (frameshift or nonsense) and families
in which at least one mutation was a missense mutation
or the silent 306ArG mutation (table 3). In the first
group, which mostly included patients with the 744delA
mutation, the mean age at onset of the disease was
years, whereas in the second group the mean age9 5
at onset was years. In the second group, the22 16
mean age at onset for patients with nonconservativemis-
sense mutations (R59W, E141K, and R221W), which
affected amino acids conserved during evolution, was
years and was not different from the mean age10 3
at onset associated with truncating mutations. The three
semiconservative mutations not conserved in related
proteins (R192H, A120T, andH101Q) and the potential
mutation 306ArG appeared to be associated with a
milder presentation of the disease, with later onset (mean
age ; , for the difference between the29 15 P ! .01
group with truncating mutations and that with semi-
conservative mutations) and/or no aggravation over 5
years. Patients in families 14 (R192H), 21 (306ArG),
and 24 (A120T) had normal, increased, and partially
decreased deep tendon reflexes, respectively, whereas all
others, including the four patients with missense mu-
tation H101Q, had abolished deep tendon reflexes. In-
terestingly, retinopathy was associated with the H101Q
mutation (present in three of four patients), whereas it
was very rarely associated with the other mutations.
Discussion
FIVE was first described byBurck et al.(1981), and,
despite the small number of cases reported initially, phe-
notypic variability appeared to be very great, ranging
from severe Friedreich ataxia–like presentation (AVED)
(Stumpf et al. 1987; Ben Hamida et al. 1993b) to mild
neurological impairment (Sokol et al. 1988) and very
late onset of disease (Yokota et al. 1987). We and others
have found that AVED is due to mutations in the a-TTP
gene (Gotoda et al. 1995; Ouahchi et al. 1995; Hentati
et al. 1996). In this article, we report the identification
of seven novel mutations. In addition, mutation-iden-
tification and clinical records were obtained for 37 pa-
tients in 23 families. This represents the largest group
of AVED patients collected, and the compilation of these
data, plus data from six other patients with documented
mutations reported elsewhere (Gotoda et al. 1995; Hen-
tati et al. 1996; Yokota et al. 1996, 1997), allowed us
to explore the clinical overlap and differences from Frie-
dreich ataxia, with which AVED is often confused. Age
at onset appeared to be very broad, being within the
range of 2–52 years, but most patients had onset at age
X20 years. Several features are shared with Friedreich
ataxia, including cerebellar ataxia, loss of deep tendon
reflexes, vibratory-sense disturbances, dysarthria,muscle
weakness, and Babinski sign. However, cardiomyopathy
is significantly rarer in AVED than in Friedreich ataxia
( ), whereas head titubation (28% of patients;P ! .0005
) and dystonia (13% of patients) appeared toP ! .0005
be specific to AVED. The clinical differences between
Friedreich ataxia and AVED may point to subtle differ-
ences in pathological pathways; yet, recent results in-
dicate that Friedreich ataxia is also related to oxidative
stress (Babcock et al. 1997; Foury and Cazzalini 1997;
Koutnikova et al. 1997), against which vitamin E pre-
sumably has a major protective role.
The 744delA mutation is clearly the most frequent
mutation, with a founder effect originating from North
Africa (Ouahchi et al. 1995). However, one North Af-
rican patient (family 31) was homozygous for another
mutation, 486delT, which also was found in two fam-
ilies, one from Canada (western Ontario; family 20) and
the other from the United States (Hentati et al. 1996),
suggesting a very wide geographic distribution. Three
other mutations were found in two or more independent
families. Mutation 513insTT was found in four fami-
lies—two Italian families (21 and 28) and two American
families with European ancestry (Danish [family 14] and
German) (Hentati et al. 1996).We also found the R134X
mutation in two independent Canadian families, one
from Que´bec (family 18) and the other from western
Ontario (family 20). However, linked haplotypes sug-
gested the occurrence of two independent CpG muta-
tions resulting in the R134X mutation. Finally, the
H101Q mutation was found in four independent Jap-
anese families but appears to be restricted to Japan.
The large number of patients and mutations collected
in this study permitted clinical/molecular correlation of
AVED. For the few patients who were compound het-
erozygotes for a frameshift mutation and a missense mu-
tation (including the 306ArG mutation, which has an
uncertain pathogenicity), we assumed that clinical status
was driven by the missense mutation, since the latter is
likely to allow production of some partially functional
protein. The severity of the disease clearly can be mod-
ulated by different, nongenetic factors including the
amount of vitamin E in the daily diet and the time of
initiation and dosage of vitamin E supplementation,
once the biochemical diagnosis has beenmade.However,
the phenotype associated with the three semiconserva-
tive missense mutations (R192H, A120T, and H101Q)
and the potential 306ArG mutation appears to be
milder than that seen in the majority of cases. The partial
loss of function associated with mutations R192H and
H101Q is corroborated by the results of previous stud-
ies, which used deuterated forms of a-tocopherol ster-
eoisomers (RRR and SRR) (Traber et al. 1993). In the
study of the function of the hepatic a-TTP in normal
humans, a marked preference for the RRR stereoisomer
over the SSR form of a-tocopherol was found. The abil-
ity to discriminate between the isomers also was dem-
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Table 3
Correlation between Genotype (Grouped by Mutation) and Clinical Findings
MUTATION TYPE
AND FAMILYa
GEOGRAPHIC
ORIGIN CONSANGUINITY MUTATION
VITAMIN E
LEVELb
(mg/liter)
AGE AT ONSET
(years)
CLINICAL FEATURESc
WC
(years) Pd CA D TRe VSD WL B HT CM Dyst Rf
Truncating:
1 Tunisia Yes 744delA/744delA .5 8 !27    a     
.6 8 !25    a     
) 9 Died at 21    a    
2 Tunisia Yes 744delA/744delA .9 18 !30    a     
.3 12 !28    a     
.5 15 !23    a     
.5 10 !30    a     
.6 6 28    a     
5 Italy Yes 744delA/744delA 2 13 150    a      
1.5 12 144    a  /     
7 Tunisia Yes 744delA/744delA !1 3 16    a       
8 Morocco Yes 744delA/744delA .6 7 13    a       
1.3 6 17 na   a      
10 Italy Yes 744delA/744delA .8 13 124    a       
16 Italy 744delA/744delA !1 19 124    a     
19 Algeria Yes 744delA/744delA .5 3 123    a       
.9 12 113 na /  a       
23 Tunisia Yes 744delA/744delA !1 4 115    a /      
29 Italy No 744delA/744delA .25 12 15    a       
30 Morocco Yes 744delA/744delA .5 15 123    a       
12 France No 744delA/205-1GrC 1.2 2 13    a       /
13 Germany Yes 530AGr6/530AGr6 !1 3 127  / / a     
18 Canada Yes R134X/R134X !1 5 11   a       
20 Canada No R134X/486delT !2 6 17    a  /     
31 Morocco Yes 486delT/486delT !1 8 19 na   a     /  
Hentati United States 486delT/486delT !1.1 7 17    a      
Hentati United States
(Germany)
No 513insTT/513insTT 1.0 3 20    a       
28 Italy No 513insTT/513insTT !2.1 5 21    a       
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Missense:
6 Albania Yes R221W/R221W ) 10     
) 14     
) 12     
11 France Yes E141K/E141K 1.3 8 128   / a  /     
26 Portugal Yes R59W/R59W .3 7 117    a       
14 United States No R192H/513insTT 1.8 6 135    n      
(Denmark and 1.8 27 139    n      
England) 1.2 121 133 na /  n      
21 Italy No 306ArG?/513insTT 1.2 ) 131   / i    /   
3.3 16 128    i       
24 Belgium Yes A120T/A120T 1 21 124    d       /
Gotoda Japan No H101Q/H101Q 1.2 52 172    a       
Yokota Japan Yes H101Q/H101Q 1.5 38 147    a       
Yokota Japan No H101Q/H101Q 1.0 30 155    a       
Yokota Japan No H101Q/H101Q 2.3 52 159    a       
Undetected:
15 Puerto Rico Yes ?/? !1 13 21    a      
22 France No ?/? .5 38 153    a     
25 Italy No ?/? !1 62 165    d    /   
27 Italy Yes ?/? 2.2 11 116    n       
a“Hentati” indicates families from the study by Hentati et al. (1996); “Gotoda” indicates those from the study by Gotoda et al. (1995); and “Yokota” indicates those from the
studies by Yokota et al. (1996, 1997).
bNormal level mg/ml.8.7 3.7
cWC  age when first in wheelchair; P  progressive worsening over 5 years; CA  cerebellar ataxia; D  dysarthria; TR  tendon reflexes in the lower limbs (knees and
ankles); VSD  vibration-sense disturbances; WL  weakness in legs; B  Babinsky sign; HT  head titubation; CM  cardiomyopathy; Dyst  dystonia; and R  retinopathy.
A plus sign () indicates the presence of a symptom; a minus sign () indicates the absence of a symptom.
dna  not applicable.
en  normal; i  increased; d  decreased; and a  abolished.
fA plus sign () indicates presence of retinitis pigmentosa; a plus and a minus sign (/) indicates moderately reduced amplitudes on electroretinogram.
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Table 4
Compared Frequency of Clinical Signs between Friedreich Ataxia and AVED
Patients
CLINICAL SIGN
FREQUENCY AMONG
(%)
Friedreich Ataxia Patients
AVED Pa-
tients from
This Study
( )an  43
From Du¨rr et al. 1996
( )an  140
From Harding 1981
( )an  115
Gait and limb
ataxia 99 99 98
Dysarthria 91 97 77 ( )n  39
Lower-limb
areflexia 87 99 85 ( )n  40
Loss of vibra-
tory sense 78 73 86
Extensor plantar
reflexes 79 89 58
Muscle weak-
ness in lower
limb 67 88 35 ( )n  31
Head titubation 0b ) 28 ( )n  39
Cardiomyopathy 63 ( )n  75 ) 19 ( )n  42
Diabetes or im-
paired glucose
tolerance 32 ( )n  61 10 0 ( )n  16
a Unless otherwise noted in parentheses after the corresponding frequency.
b Data from A. Du¨rr (personal communication).
onstrated in perfused monkey livers in vitro. Patients
with R192H or H101Qmutations were still able to pref-
erentially incorporate the natural RRR stereoisomer into
VLDL—to a lesser extent than normal subjects—and
were labeled “discriminators” (table 5).
These patients contrasted with other patients who had
a complete loss of the capacity to preferentially incor-
porate the natural a-tocopherol stereoisomer into VLDL
(labeled “nondiscriminators”). In four of these patients,
the mutations have been characterized, and they are
homozygous for severe truncating mutations
(530AGrGTAAGT, 744delA, 486delT, and R134X) (ta-
ble 5). Interestingly, they all are associated with a severe,
early-onset form of the disease. All other truncating mu-
tations and the nonconservative missense mutations
(R59W, E141K, and R221W) also seemed to be asso-
ciated with the severe form of the disease, suggesting
that they also result in complete loss of function, al-
though the patients were not studied for their ability to
discriminate between RRR and SRR isomers of a-to-
copherol. This points to an important role for amino
acids R59, E141, and R221, which are invariant or con-
served in the related CRALB and SEC14 proteins (Arita
et al. 1995). All cases with cardiomyopathy were
associated with frameshift or R221W (one case)
mutations.
Of particular interest was the fact that retinitis was
associated more highly with the H101Q mutation (Yok-
ota et al. 1996) than with other mutations. The H101Q
mutation is also associated with a mild phenotype and
very late onset. It is conceivable that, in the case of the
H101Q mutation, the presence of retinitis is associated
with older age of the patient (onset of visual symptoms
occurred at age 142 years [Yokota et al. 1987, 1996])
and longer disease duration. One patient homozygous
for the 744delA mutation (the first child of family 8)
showed early onset of visual impairment and retinal pig-
ments (Amiel et al. 1995). At least two other families
with isolated vitamin E deficiency and early onset of
symptoms had abnormal fundoscopy, described as yel-
lowish-white spots of the peripheral retina (Rayner et
al. 1993; Shorer et al. 1996). Mutations of the a-TTP
gene in these two families have not been reported yet.
Our experience has shown that, in AVED patients,
there is no limitation to or difficulty with the absorption
of vitamin E by the intestinal tract (Kayden and Traber
1993). The administration of vitamin E supplements in
divided doses daily has resulted in cessation of progres-
sion of the neurological symptoms and signs and in ame-
lioration of established neurological abnormalities, in a
number of patients (Kohlschu¨tter et al. 1988; Yokota et
al. 1997). Our experience is that, for adults, the admin-
istration of 800 mg RRR a-tocopherol twice daily, with
meals that contain fat, results in plasma a-tocopherol
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Table 5
Correlation between Genotype and Discrimination among Stereoisomers of a-Tocopherol
Familya Patientb Mutation
Vitamin E Level
(mg/liter)
Age at Onset
(years) Discrimination Statusc
Hentati 4 513insTT/513insTT 1.0 3 Nondiscriminator
18 8 R134X/R134X !1 5 Nondiscriminator
13 6 530AGr6/530AGr6 !1 3 Nondiscriminator
16 9 744delA/744delA !1 19 Nondiscriminator
14 1 R192H/513insTT 1.8 6 Discriminator
14 2 R192H/513insTT 1.8 27 Discriminator
Gotoda 7 H101Q/H101Q 1.2 52 Discriminator
a “Hentati” indicates a family from the study by Hentati et al. (1996); “Gotoda” indicates a family
from the study by Gotoda et al. (1995);
b Numbering is according to Traber et al. (1993). The discrimination status of patient 9 is described in
the “note added in proof” in the study byTraber et al. (1993).
c RRR and SRR a-tocopherol stereoisomer discrimination, from Traber et al. (1993).
levels that are at or above the normal range. This dose
is far below our recommended dose for patients with
abetalipoproteinemia, which is 150 mg RRR a-tocoph-
erol/kg body weight daily, since in abetalipoproteinemia
the malabsorption and lipoprotein abnormalities make
transfer into the CNS extremely difficult.
Despite the differences between the clinical presen-
tation of AVED patients and that of Friedreich ataxia
patients, 19 (of 38) AVED patients initially were diag-
nosed as having Friedreich ataxia, several years before
serum vitamin E measurement was undertaken, resulting
in late initiation of vitamin E supplementation. The sig-
nificant number of new cases reported in this study in-
dicates that AVED, originally thought to represent only
a very small proportion of all recessive ataxias, is not
so rare, stressing again the importance of not missing
the diagnosis of this treatable condition, in order to in-
stitute therapy promptly.
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